Barclays PLC Ab Cellera Biologics Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
A detailed history of Barclays PLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Barclays PLC holds 172,358 shares of ABCL stock, worth $675,643. This represents 0.0% of its overall portfolio holdings.
Number of Shares
172,358
Previous 120,657
42.85%
Holding current value
$675,643
Previous $689,000
13.21%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ABCL
# of Institutions
171Shares Held
120MCall Options Held
264KPut Options Held
254K-
Baker Bros. Advisors LP New York, NY27.5MShares$108 Million1.58% of portfolio
-
Baillie Gifford & CO23.2MShares$90.9 Million0.08% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$41.7 Million0.06% of portfolio
-
Capital World Investors Los Angeles, CA8.35MShares$32.7 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$17.8 Million0.02% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.12B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...